Protalix BioTherapeutics, Inc. (PLX)

Market Cap	110.16M
Revenue (ttm)	63.63M
Net Income (ttm)	10.62M
Shares Out	72.95M
EPS (ttm)	0.05
PE Ratio	31.00
Forward PE	18.25
Dividend	n/a
Ex-Dividend Date	n/a

Volume	309,988
Open	1.50
Previous Close	1.51
Day's Range	1.47 - 1.59
52-Week Range	1.13 - 3.55
Beta	1.16
Analysts	Strong Buy
Price Target	10.00 (+545.16%)
Earnings Date	Nov 6, 2023

About PLX

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. It also develops PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-115, a plant cell-expressed recombinant PEGylated Uricas...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 15, 1998
• Employees: 193
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: PLX

Financial Performance

In 2022, PLX's revenue was $47.64 million, an increase of 24.22% compared to the previous year's $38.35 million. Losses were -$14.93 million, -45.88% less than in 2021.

Analyst Forecast

According to one analyst, the rating for PLX stock is "Strong Buy" and the 12-month stock price forecast is $10.0.

Price Target

$10.0

(545.16% upside)

Analyst Consensus: Strong Buy